FILE:CELG/CELG-8K-20061212170521.txt.gz
EVENTS:	Entry into a Material Definitive Agreement	Financial Statements and Exhibits
TEXT:
ITEM: Entry into a Material Definitive Agreement
ITEM: Financial Statements and Exhibits
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 8, 2006 CELGENE CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-16132 22-2711928 - -------------------------------------------------------------------------------- (State or other jurisdiction of (Commission File Number) (IRS Employer incorporation) Identification No.) 86 Morris Avenue, Summit, New Jersey 07901 - -------------------------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (908) 673-9000 - -------------------------------------------------------------------------------- (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. On December 11, 2006, Celgene Corporation, or the Company, announced that on December 8, 2006 it entered into a material definitive agreement for the purchase of an active pharmaceutical ingredient (API) manufacturing facility from Siegfried Ltd. located in Zofingen, Switzerland, and simultaneously consummated such purchase. The Company is purchasing the assets for approximately a total of $46.5 million in cash, with an initial payment of $12.5 million. The manufacturing facility has the capability to produce multiple drug substances and initially will be used to produce REVLIMID(R) to supply global markets. Attached hereto as Exhibit 99.1 is the Press Release announcing the transaction. ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS. Exhibit 99.1 Press Release dated December 11, 2006 announcing the acquisition of an API manufacturing facility from Siegfried Ltd. SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELGENE CORPORATION Date: December 12, 2006 By: /s/ Robert J. Hugin ----------------------------------- Name: Robert J. Hugin Title: President and Chief Operating Officer
EXHIBIT INDEX Exhibit No. Description - ----------- ----------- Exhibit 99.1 Press Release dated December 11, 2006 announcing the acquisition of an API manufacturing facility from Siegfried Ltd.

Exhibit 99.1 Contact: Robert J. Hugin Brian P. Gill President & COO Senior Director PR/IR Celgene Corporation Celgene Corporation (908) 673-9102 (908) 673-9530 CELGENE ACQUIRES API MANUFACTURING FACILITY IN EUROPE SUMMIT, NJ - (DECEMBER 11, 2006) - Celgene Corporation (NASDAQ: CELG) announced that it has acquired active pharmaceutical ingredient (API) manufacturing facility from Siegfried Ltd. (SWX: SFZN), a manufacturer of high-quality pharmaceutical products located in Zofingen, Switzerland. Celgene is purchasing the assets for approximately a total of $46.5 million in cash, with an initial payment of $12.5 million. The manufacturing facility has the capability to produce multiple drug substances and initially will be used to produce REVLIMID to supply global markets. The facility also may be used to produce drug substance for future Celgene drugs and drug candidates. This acquisition further expands our global commercial manufacturing capabilities and furthers the goal of Celgene to maintain its strategic control of production worldwide. The API manufacturing plant acquired from Siegfried has been approved by United States and European regulatory authorities to produce and supply drug substance for both of these major markets. Siegfried, with 130 years of pharmaceutical and chemical manufacturing experience, also will continue to collaborate with Celgene to provide chemical intermediates, quality control systems, analytical testing and certain other technical support services. "This asset acquisition further extends our global infrastructure and supports our objective to strategically control the production of REVLIMID worldwide," said Robert J. Hugin, President and Chief Operating Officer at Celgene Corporation. ABOUT CELGENE Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com. THIS RELEASE CONTAINS FORWARD-LOOKING STATEMENTS WHICH ARE SUBJECT TO KNOWN AND UNKNOWN RISKS, DELAYS, UNCERTAINTIES AND OTHER FACTORS NOT UNDER THE COMPANY'S CONTROL, WHICH MAY CAUSE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF THE COMPANY TO BE MATERIALLY DIFFERENT FROM THE RESULTS, PERFORMANCE OR OTHER EXPECTATIONS EXPRESSED OR IMPLIED BY THESE FORWARD-LOOKING STATEMENTS. THESE FACTORS INCLUDE RESULTS OF CURRENT OR PENDING RESEARCH AND DEVELOPMENT ACTIVITIES, ACTIONS BY THE FDA AND OTHER REGULATORY AUTHORITIES, AND OTHER FACTORS DESCRIBED IN THE COMPANY'S FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION SUCH AS OUR 10K, 10Q AND 8K REPORTS. # # #


